FOR SALE

Quote

anonymous

Guest
Rumors are flying about Esperion being a ripe target for a buyout. With the outcomes data and new indication the likelihood increases. Big Pharma is needed to maximize value and wrestle with managed care, and they are hungry for a deal. Its not a question of if, but a question of who, when and how much will they pay.
 




anonymous said:
Rumors are flying about Esperion being a ripe target for a buyout. With the outcomes data and new indication the likelihood increases. Big Pharma is needed to maximize value and wrestle with managed care, and they are hungry for a deal. Its not a question of if, but a question of who, when and how much will they pay.
Click to expand...


So who is going to buy us?
 




Anthony just shut up. Nobody is going to buy this dumpster fire. Only Dr Reddy Pharma would buy us. Will be cut up and sold to 3rd world distribution centers and be a second or 3rd line treatment t behind generic statins
 
















anonymous said:
Would they fire us all??
Click to expand...
Depends on the buyer. Maybe kept on. Maybe let go with severance. Maybe have to re-interview for your old job. Who knows.

Stock will vest if you’re employed through buyout which is a good thing. And likely a handsome severance if you’re not kept on. Other companies’ circle buyout employees like vultures. You won’t be unemployed long. Buyouts are a good thing in pharma.
 




anonymous said:
Rumors are flying about Esperion being a ripe target for a buyout. With the outcomes data and new indication the likelihood increases. Big Pharma is needed to maximize value and wrestle with managed care, and they are hungry for a deal. Its not a question of if, but a question of who, when and how much will they pay.
Click to expand...
WHAT RUMORS LOL
 




Every company that is bought in pharma gets hosed. They won't keep this sales team and forget about a nice severance. That only happens in the movies. All management will be clipped also. Esperion doesn't have an impressive staff.
 




anonymous said:
Rumors are flying about Esperion being a ripe target for a buyout. With the outcomes data and new indication the likelihood increases. Big Pharma is needed to maximize value and wrestle with managed care, and they are hungry for a deal. Its not a question of if, but a question of who, when and how much will they pay.
Click to expand...

Good Lord.
Who wrote this nonsense.
A Scientific Hire, Highly Tenured Trained Lipid Expert ?
Figures
 




anonymous said:
Depends on the buyer. Maybe kept on. Maybe let go with severance. Maybe have to re-interview for your old job. Who knows.

Stock will vest if you’re employed through buyout which is a good thing. And likely a handsome severance if you’re not kept on. Other companies’ circle buyout employees like vultures. You won’t be unemployed long. Buyouts are a good thing in pharma.
Click to expand...

This is not true.
For the idiots drinking the Kool-Aid.
Ask the idiot who posted this for his name.
What a joke.
 








DS is an obvious likely acquirer as they’ve already made an investment and have agreed to take over manufacturing cost. They’ve seen a tremendous lift in business overseas and with the new label it’s going to happen here. Things will heat up post ACC.
 




I’m hearing more about Novartis. They have fought to get inclisiran off the ground, partially due to a lack of outcomes data. The size and might of NVS could quickly catapult catapult bempo into a drivers seat position with prescribers and managed care. Having a suite of lipid lowering open agents to offer really does increase bargaining strength. It will be interesting to see how this plays out over the next 6 months or so.
 




anonymous said:
I’m hearing more about Novartis. They have fought to get inclisiran off the ground, partially due to a lack of outcomes data. The size and might of NVS could quickly catapult catapult bempo into a drivers seat position with prescribers and managed care. Having a suite of lipid lowering open agents to offer really does increase bargaining strength. It will be interesting to see how this plays out over the next 6 months or so.
Click to expand...


Nope, it will be Merck.
 












I hear your brother, we’ve got a pretty sweet deal here for for sure. I love the single point of accountability, and not having to figure out some matrix collaborative selling scenario. It does stand the reason though that we’re going to get gobbled up by someone in big Pharma and we’ll probably get a great severance package if they decide to let us go so that’s not all bad. But yeah it's kind of hard to be always thinking about where your next opportunity might be, For now, though we’ve got it good.
 




anonymous said:
I hear your brother, we’ve got a pretty sweet deal here for for sure. I love the single point of accountability, and not having to figure out some matrix collaborative selling scenario. It does stand the reason though that we’re going to get gobbled up by someone in big Pharma and we’ll probably get a great severance package if they decide to let us go so that’s not all bad. But yeah it's kind of hard to be always thinking about where your next opportunity might be, For now, though we’ve got it good.
Click to expand...

A Scientific Hire puffing up his chest on possibilities. Foolishness.
Word of advice. Don’t spend the windfall today that your imagination is dreaming up.
 








Top Bottom
Back
Quote